Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 1.00 |
| ▸ | CDK2 | P24941 | 8/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 5/20 | 1.00 |
| ▸ | GSK3A | P49840 | 4/20 | 1.00 |
| ▸ | PLK4 | O00444 | 3/20 | 1.00 |
| ▸ | AURKA | O14965 | 3/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 3/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 3/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 3/20 | 1.00 |
| ▸ | STK3 | Q13188 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 2/20 | 1.00 |
| ▸ | BLK | P51451 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | MAP4K4 | O95819 | 6/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.57 |
| ▸ | KDR | P35968 | 3/20 | 0.57 |
| ▸ | HIPK2 | Q9H2X6 | 3/20 | 0.57 |
| ▸ | CDK1 | P06493 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5937366 | 0.76 | CYP1A2 (1.00) | GSK3BCDK2CDK5GSK3APLK4 | |
| SCHEMBL2261826 | 0.72 | GSK3B (0.67) | GSK3BCDK2CDK5GSK3APLK4 | |
| SCHEMBL2264395 | 0.72 | GSK3B (1.00) | GSK3BCDK2CDK5GSK3APLK4 | |
| SCHEMBL2260312 | 0.72 | GSK3B (1.00) | GSK3BCDK2CDK5GSK3APLK4 | |
| SCHEMBL12367158 | 0.72 | GSK3B (0.56) | GSK3BCDK2CDK5GSK3APLK4 | |
| SCHEMBL477913 | 0.72 | CDK2 (0.56) | GSK3BCDK2CDK5GSK3APLK4 | |
| SCHEMBL11528200 | 0.70 | CYP1A2 (0.56) | GSK3BCDK2CDK5GSK3APLK4 | |
| SCHEMBL2259464 | 0.69 | GSK3B (0.61) | GSK3BCDK2CDK5GSK3APLK4 | |
| SCHEMBL2262358 | 0.69 | GSK3B (0.61) | GSK3BCDK2CDK5GSK3APLK4 | |
| SCHEMBL5697347 | 0.68 | ACVR1 (0.67) | GSK3BCDK2CDK5GSK3APLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994160-B2 | Pyridazine compounds as glycogen synthase kinase 3 inhibitors | ABBOTT GMBH & CO. KG (DE) | 2011-08-09 | — | — | US | claimed |
| US-20090325937-A1 | Pyridazine Compounds as Glycogen Synthase Kinase 3 Inhibitors | ABBOTT GMBH & CO. KG (DE) | 2009-12-31 | — | — | US | claimed |
| EP-1902055-A1 | PYRIDAZINE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | Abbott GmbH & Co. KG (DE) | 2008-03-26 | — | — | EP | claimed |
| WO-2007006566-A1 | PYRIDAZINE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2007-01-18 | — | — | WO | claimed |
| US-7994160-B2 | Pyridazine compounds as glycogen synthase kinase 3 inhibitors | ABBOTT GMBH & CO. KG (DE) | 2011-08-09 | — | — | US | disclosed |
| US-7994160-B2 | Pyridazine compounds as glycogen synthase kinase 3 inhibitors | ABBOTT GMBH & CO. KG (DE) | 2011-08-09 | — | — | US | disclosed |
| US-20090325937-A1 | Pyridazine Compounds as Glycogen Synthase Kinase 3 Inhibitors | ABBOTT GMBH & CO. KG (DE) | 2009-12-31 | — | — | US | disclosed |
| US-20090325937-A1 | Pyridazine Compounds as Glycogen Synthase Kinase 3 Inhibitors | ABBOTT GMBH & CO. KG (DE) | 2009-12-31 | — | — | US | disclosed |
| EP-1902055-A1 | PYRIDAZINE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | Abbott GmbH & Co. KG (DE) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007006566-A1 | PYRIDAZINE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325937-A1 | Pyridazine Compounds as Glycogen Synthase Kinase 3 Inhibitors | GSK3B, GSK3A, GYS2 | GSK3B 1/4885CDK2 32/4885CDK5 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.